Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ernexa Therapeutics Inc.ERNA · Entity 8278 | Director · President and CEO | January 12, 2023 | January 14, 2023 |
| Tempest Therapeutics, Inc.TPST · Entity 7734 | Director · CEO and President · 10% owner | March 24, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ernexa Therapeutics Inc.
Report date January 12, 2023 · Filed January 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.84 · Expires 2033-01-12 | Direct | 132,003 |
Reported balance
After 2023-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-12 · Grant · Acquired 132,003 · Balance 132,003 F1: The stock options vests and becomes exercisable over three years (subject to continued service), with 110,043 of the shares vesting on the grant date, and the remaining shares vesting in 36 substantially equal monthly tranches on the first day of each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vests and becomes exercisable over three years (subject to continued service), with 110,043 of the shares vesting on the grant date, and the remaining shares vesting in 36 substantially equal monthly tranches on the first day of each month thereafter.
Tempest Therapeutics, Inc.
Report date March 24, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Factor Bioscience Inc. | 231,482 |
Reported balance
After 2026-03-24 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-03-24 · Purchase · Acquired 231,482 · Balance 231,482 F2: The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16. F1: On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026. F3: The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor. |
| Series A Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.16 | IndirectBy Factor Bioscience Inc. | 231,482 |
Reported balance
After 2026-03-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-24 · Purchase · Acquired 231,482 · Balance 231,482 F1: On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026. F2: The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16. F4: The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval. F3: The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor. |
| Series B Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.16 | IndirectBy Factor Bioscience Inc. | 231,482 |
Reported balance
After 2026-03-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-24 · Purchase · Acquired 231,482 · Balance 231,482 F1: On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026. F2: The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16. F5: The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval. F3: The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026.
F2: The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16.
F3: The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor.
F4: The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval.
F5: The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 24, 2026 Filed Mar 25, 2026 21:32 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | PurchaseCommon Stock | 231,482 | $2.16 | $500,001.12 |
DisclosureSEC source: 0001931356-26-000011 · form4-03252026_090332.xml · nonDerivative · entry 1 Angel Matthew · CIK 0001931356 · Director · CEO and President · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Factor Bioscience Inc. Disclosed balance after: 231,482 F1 · ownership.nature: The shares are held by Factor Bioscience Inc. ("Factor"). The Reporting Peron is the chief executive officer and chairman of the board of directors of Factor and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| March 24, 2026 Filed Jun 23, 2026 20:56 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | PurchaseSeries B Warrant (right to buy) · Derivative | 231,482 | Not disclosed Strike: $2.16 | Not disclosed |
DisclosureSEC source: 0001193125-26-279703 · ownership.xml · derivative · entry 3 Angel Matthew · CIK 0001931356 · Director · CEO and President · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Factor Bioscience Inc. Disclosed balance after: 231,482 Underlying: Common Stock · 231,482 shares Expires not disclosed F1 · kind: On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026. F2 · price: The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16. F5 · derivative.exercise_date: The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval. F5 · derivative.expiration_date: The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval. F3 · ownership.nature: The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor. Read SEC document |
| March 24, 2026 Filed Jun 23, 2026 20:56 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | PurchaseSeries A Warrant (right to buy) · Derivative | 231,482 | Not disclosed Strike: $2.16 | Not disclosed |
DisclosureSEC source: 0001193125-26-279703 · ownership.xml · derivative · entry 2 Angel Matthew · CIK 0001931356 · Director · CEO and President · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Factor Bioscience Inc. Disclosed balance after: 231,482 Underlying: Common Stock · 231,482 shares Expires not disclosed F1 · kind: On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026. F2 · price: The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16. F4 · derivative.exercise_date: The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval. F4 · derivative.expiration_date: The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval. F3 · ownership.nature: The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor. Read SEC document |
| March 24, 2026 Filed Jun 23, 2026 20:56 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | PurchaseCommon Stock | 231,482 | $2.16 | $500,001.12 |
DisclosureSEC source: 0001193125-26-279703 · ownership.xml · nonDerivative · entry 1 Angel Matthew · CIK 0001931356 · Director · CEO and President · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Factor Bioscience Inc. Disclosed balance after: 231,482 F2 · price: The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16. F1 · acquired: On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026. F3 · ownership.nature: The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 21:26 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 269,621 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001931356-26-000006 · form4-02062026_090210.xml · derivative · entry 1 Angel Matthew · CIK 0001931356 · Director · CEO and President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,621 Underlying: Common Stock · 269,621 shares Expires 2036-02-03 F1 · derivative.exercise_date: This option shall vest with respect to 25% of the total number of shares underlying the option on February 4, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| January 12, 2023 Filed Jan 14, 2023 00:30 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | GrantStock Option (right to buy) · Derivative | 132,003 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001140361-23-001698 · form4.xml · derivative · entry 1 Angel Matthew · CIK 0001931356 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,003 Underlying: Common Stock, par value $0.005 per share · 132,003 shares Expires 2033-01-12 F1 · derivative.exercise_date: The stock options vests and becomes exercisable over three years (subject to continued service), with 110,043 of the shares vesting on the grant date, and the remaining shares vesting in 36 substantially equal monthly tranches on the first day of each month thereafter. Read SEC document |
| August 01, 2022 Filed Aug 4, 2022 00:01 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option (right to buy) · Derivative | 2,487,003 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001140361-22-028096 · form4.xml · derivative · entry 1 Angel Matthew · CIK 0001931356 · Director · Interim President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,487,003 Underlying: Common Stock, par value $0.005 per share · 2,487,003 shares Expires 2032-08-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable over four years (subject to continued service), with 2/48th of the shares vesting on the grant date and the remaining shares vesting in 46 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.